Loading
A phase 1/2 trial of FL115+PD-1 in advanced solid tumours, run by Suzhou Forlong Biotechnology Co., Ltd, now recruiting.
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07131202 by Suzhou Forlong Biotechnology Co., Ltd, with 130 participants planned, started 2026-01-08 and due to reach its primary completion in 2026-12-05. Interventions recorded: FL115+PD-1.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Suzhou Forlong Biotechnology and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/